Form 4 for XLO Xilio Therapeutics, Inc.

Accepted 2024-02-09 00:00:00 ET · period of report 2024-02-08 · accession 0001209191-24-003031 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2024-02-09	2024-02-08	XLO	Atlas Venture Fund XI, L.P.	10%	S - Sale	$0.64	-267	734.5K	-0.0%	-$170.88
	2024-02-09	2024-02-08	XLO	Atlas Venture Fund XI, L.P.	10%	S - Sale	$0.64	-733	2.02M	-0.0%	-$469.12

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-02-08	S	D	267	$0.64	734,546	I	—	—
2	Common	Common Stock	2024-02-08	S	D	733	$0.64	2,019,563	D See footnote	—	—	(F1) The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any. (F2) The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.